ConductScience.org, home

Paper4421998

Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.

Almon RR and 2 others. Science, 1974. Cited by 374 papers, by iCite.

Cite this record

ConductScience Library. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Papers, record 4421998. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4421998

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.
PubMed
Journal
Science
PubMed
Year
1974
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
374
iCite
Relative citation ratio, by iCite
10.4
iCite
Revised in PubMed
2019-06-18
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Almon RRR R
2Andrew CGC G
3Appel SHS H

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BungarotoxinsMajor topic
Myasthenia GravisMajor topic
Neuromuscular JunctionMajor topic
Receptors, CholinergicMajor topic
Serum GlobulinsMajor topic
Acetylcholine
Adult
Aged
Animals
Binding Sites
Binding, Competitive
Female
Humans
Iodine Radioisotopes
Male
Middle Aged
Rats

Source PubMed

Download CSV of topics

Cited by87

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 374 citations.

PMIDTitleJournalYearIn PapersSource
42908923Clinical study of eculizumab with or with not tacrolimus in the treatment of generalized myasthenia gravis.Front Immunol2026https://conductscience.org/library/papers/42908923PubMed
42308456Functional Profiling of Acetylcholine Receptor Antibodies Informs Therapeutic Outcome of FcRn Inhibitor Therapy in Myasthenia Gravis.Neurol Neuroimmunol Neuroinflamm2026https://conductscience.org/library/papers/42308456PubMed
42242900Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.J Neurol Neurosurg Psychiatry2026https://conductscience.org/library/papers/42242900PubMed
42155846Novel methods for neural IgG characterization and validation in autoimmune neurologic disorders.J Immunol Methods2026https://conductscience.org/library/papers/42155846PubMed
41118207Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/41118207PubMed
40680247AChR Autoantibody Pathogenic Properties Are Heterogeneously Distributed and Undergo Temporal Changes Among Patients With Myasthenia Gravis.Neurol Neuroimmunol Neuroinflamm2025https://conductscience.org/library/papers/40680247PubMed
40303417The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?Front Immunol2025https://conductscience.org/library/papers/40303417PubMed
39987373Myasthenia gravis in 2025: five new things and four hopes for the future.J Neurol2025https://conductscience.org/library/papers/39987373PubMed
38133144Pathophysiology of Childhood-Onset Myasthenia: Abnormalities of Neuromuscular Junction and Autoimmunity and Its Background.Pathophysiology2023https://conductscience.org/library/papers/38133144PubMed
37817097Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study.BMC Neurol2023https://conductscience.org/library/papers/37817097PubMed
35290370Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.PLoS One2022https://conductscience.org/library/papers/35290370PubMed
34784297Protease-dependent defects in N-cadherin processing drive PMM2-CDG pathogenesis.JCI Insight2021https://conductscience.org/library/papers/34784297PubMed
33365280Complement Inhibition for the Treatment of Myasthenia Gravis.Immunotargets Ther2020https://conductscience.org/library/papers/33365280PubMed
33199596Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/33199596PubMed
32547535Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.Front Immunol2020https://conductscience.org/library/papers/32547535PubMed
31482201Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.J Neurol2021https://conductscience.org/library/papers/31482201PubMed
28940642B cells in the pathophysiology of myasthenia gravis.Muscle Nerve2018https://conductscience.org/library/papers/28940642PubMed
28761905Frequencies of neuronal autoantibodies in healthy controls: Estimation of disease specificity.Neurol Neuroimmunol Neuroinflamm2017https://conductscience.org/library/papers/28761905PubMed
27127487"Warming yang and invigorating qi" acupuncture alters acetylcholine receptor expression in the neuromuscular junction of rats with experimental autoimmune myasthenia gravis.Neural Regen Res2016https://conductscience.org/library/papers/27127487PubMed
26136751Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.Front Immunol2015https://conductscience.org/library/papers/26136751PubMed

See all 87 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4421998

GET https://conductscience.org/api/papers/v1/4421998/cited_by?page=2